leadf
logo-loader
viewAnteris Technologies Ltd

Admedus Ltd to outline capital raising

au_admedus_manufacturing_facility_3_358_5797f42a7b266.jpg

Admedus Ltd (ASX:AHZ) has been granted a trading halt by the ASX, pending details of a capital raising,

During FY16, the healthcare company grew its sales to $14.1 million, up 40% on FY15 sales.

Furthermore, the company is forecasting over 50% revenue growth in the current financial year through growing the infusion sales business, CardioCel sales growth and introducing additional products.

The halt will remain in place until the opening of trade on Friday 29th July 2016, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Anteris Technologies Ltd

Price: 11.61 AUD

ASX:AVR
Market: ASX
Market Cap: $76.26 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Anteris Technologies CEO hails 'very good results' from DurAVR™ human study

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson caught up with Proactive's Andrew Scott soon after reporting that early results from its first-in-human study of its proprietary DurAVR™ aortic valve found that patient outcomes exceeded the results of what is normally expected following a...

on 19/10/20

2 min read